Abstract
Over the past year, many countries have resorted multiple times to drastic social restrictions to prevent saturation of their health care system, and to regain control over an otherwise exponentially increasing SARS-Covid-19 pandemic evolution. With the advent of data-sharing, computational approaches have gained a key role in evaluating future scenarios. To design optimal social, hospitalization and economical strategies that guarantee control over the pandemic progression, we developed a data-driven modelling framework with the aim to provide reliable near future predictions under constantly evolving social and pandemic conditions. The framework is flexible enough to be used at a single hospital, regional or national level. We used a variety of data such as social, serological, testing and clinical data to compute the infection dynamics and the hospital workload for France. We developed inference methods to calibrate model parameters from observed hospitalization statistics over adjustable time periods. We applied our model to study the age stratified pandemic evolution inside and outside hospitals until February 2021, and the competition between vaccinations and the novel delta variant. We obtained several predictions about hidden pandemic properties such as fractions of infected, infection hospitality and infection fatality ratios. We show that reproduction numbers and herd immunity levels are not universal but strongly depend on the underlying social dynamics. We find that with normal social interactions the present vaccination status and rate is not sufficient to prevent a new pandemic wave driven by the delta variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AP received funding from FRM (SPF201909009284), DH is supported by INSERM Plan Cancer and a Computational Neuroscience NIH-ANR grant. JR is supported by an ANR grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The OutcomeRea database was declared to the Commission Nationale de Informatique et des Libertes (#999,262), in accordance with French law, and this study was approved by the institutional review board of Clermont Ferrand. Informed consent was not required because the study did not modify patients management and the data were anonymously collected.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes